Opexa Goes Into Hold Mode, Awaiting Secondary Progressive MS Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech cuts staff by 30%, hoping for good news from Phase IIb trial due in the fourth quarter. Status of second candidate nearing the clinic is uncertain.
You may also be interested in...
Back In The Saddle: Texas Biotech Opexa Re-Enters The Clinic With MS Immunotherapy
After a series of restructurings, a manufacturing upgrade, multiple meetings with FDA and a modest fundraising, Opexa is initiating a Phase IIb trial of its renamed T-cell immune therapy Tcelna, this time in secondary progressive MS.
Opexa Pins Hope On Failed MS Vaccine’s Relapse Rate
More baseline lesions for personalized drug group cited in Phase IIb blowup
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.